

Opening Address

- 09:45 – 10:00

Masatoshi Hori, Representative of AMED iD3 Catalyst Unit

Yoshinao Mishima, President, Japan Agency of Medical Research and Development

Basic Research and Its Application

- 10:00 – 12:10 **Chair: Ichiro Kurane,**

■ Initiatives of Coronavirus Task Force

Koichi Fukunaga, Professor

Pulmonary Division, Department of Medicine, Keio University School of Medicine

■ SARS-CoV-2 study using respiratory organoids and iPS cells

Kazuo Takayama, Junior Associate Professor

Center for iPS Cell Research and Application, Kyoto University

■ The roles of nucleus for SARS-CoV-2 propagation

Toru Okamoto, Professor

Research Institute for Microbial Diseases, Osaka University

■ Unravelling antiviral activity and antigen recognition by SARS-CoV-2-specific cytotoxic T lymphocytes

Takamasa Ueno, Professor

Joint Research Center for Human Retrovirus Infection, Kumamoto University

■ Profiling SARS-CoV-2 immunity and its application

Yoshimasa Takahashi, Director

Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases

■ Broadly protective vaccine development for SARS-related Viruses

Tomohiro Kurosaki, Professor

Immunology Frontier Research Center (IFReC) / Center for Infectious Disease Education and Research (CiDER), Osaka University, Center for Integrative Medical Sciences, RIKEN

Development of Therapeutic Drugs

● 13:00 – 15:00 **Chair: Shuichi Tawara**

● 15:30 – 17:30 **Chair: Toshi Akashi**

■

■ **Establishment of neutralizing antibodies for mutated SARS-CoV-2 virus**

Saya Moriyama, Senior Researcher

National Institute of Infectious Diseases

■ **Development of synthetic antibody molecules with potent neutralizing activity against SARS-CoV-2**

Yasumasa Iwatani, Department Chief

National Hospital Organization Nagoya Medical Center Clinical Research Center

■ **Research and development of therapeutic strategy for COVID-19 using neutralizing monoclonal antibodies**

Shuzo Matsushita, Specially Appointed Professor

Division of Clinical Retrovirology, Joint Research Center for Human Retrovirus Infection, Kumamoto University

■ **Evaluation of the coagulation profile and the importance of pulmonary microthrombosis in COVID-19**

Daisuke Kasugai, Assistant Professor

Department of Emergency Medicine, Nagoya University Hospital

■ **Development of Antisense Oligonucleotides for the Treatment of COVID-19**

Satoshi Obika, Professor

Graduate School of Pharmaceutical Sciences, Osaka University

■ **Research program to create new therapeutic peptide drug candidates for COVID-19**

Hidenori Mikamiyama, Director

Laboratory for Advanced Medicine Research, SHIONOGI & CO., LTD.

■ **Development of Anti-COVID-19 Therapeutics and Its Perspective**

Hiroaki Mitsuya, Director

National Center for Global Health and Medicine Research Institute

■ **Development of nucleoside antimetabolites toward emerging/reemerging infectious diseases including novel coronavirus disease (COVID-19)**

Noriaki Minakawa, Professor

Graduate School of Pharmaceutical Science, Tokushima University

Katsumi Maenaka, Professor

Faculty of Pharmaceutical Sciences, Hokkaido University

Thursday, January 13, 2022

Diagnostic Drugs and Prediction of Severe COVID-19

● 10:00 – 12:00 **Chair: Teruhide Yamaguchi**

■ **Development of a CRISPR-based viral RNA detection technology**

Hiroshi Nishimasu, Professor

The University of Tokyo

■ **The presence of anti-type I interferon is a risk factor of severe COVID-19**

Satoshi Okada, Professor

Department of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Sciences

■ **Clinical and basic analysis on Long COVID**

Masaya Sugiyama, Vice Project Leader

National Center for Global Health and Medicine

■ **Clinical application for predicting the severity of COVID-19 using artificial intelligence**

Kazuki Taoka, Assistant Professor

The University of Tokyo

■ **The possibility of IL-6 and SARS-CoV-2 RNA in plasma as a guide for therapeutic efficacy in critically ill COVID-19**

Mototsugu Nishii, Lecturer

Emergency medicine, Yokohama City University

Basic Research

● 13:00 – 15:00 Chair: **Tadahito Kanda**

■ **Elucidation of the pathophysiology of the sequelae of coronavirus disease 2019 using a multidisciplinary approach**

Makoto Ishii, Associate Professor

Keio University School of Medicine

■ **Platform for the rational design of middle-sized synthetic compounds to inhibit the Protein-Protein Interaction causing COVID-19**

Masanori Osawa, Professor

Keio University Faculty of Pharmacy

■ **Research for the control of COVID-19 in Africa based on the best use of Hokudai Center for Zoonosis Control in Zambia**

Hirofumi Sawa, Professor

International Institute for Zoonosis Control, Hokkaido University

Haruka Abe, Assistant Professor

Institute of Tropical Medicine, Nagasaki University

■ **Seroepidemiological study and virus genome analysis of SARS-CoV-2 in Indonesia**

Yasuko Mori, Professor

Division of Clinical Virology, Kobe University Graduate School of Medicine

Development of COVID-19 Vaccines

- 15:30 – 17:30 Chair: **Keiji Hirai**

- **Clinical Development of "COVID-19 Vaccine Moderna intermuscular injection" in Japan**

Mitsuhiro Mori, Head of Japan Development

Global Vaccine Business Unit, Takeda Pharmaceutical Company Ltd.

- **Generation of a COVID-19 vaccine based on vaccinia virus vector**

Fumihiko Yasui, Project Leader

Viral Infection Control Project, Tokyo Metropolitan Institute of Medical Science

- **Development of Intranasal Sendai Virus Vector-based Vaccine against COVID-19**

Ryutaro Shimazaki, Executive Vice President

ID Pharma Co., Ltd.

- **Development of Replicon Vaccine against Novel Coronavirus Infection (COVID-19)**

Wataru Akahata, Representative Executor & Chief R&D Officer

VLP Therapeutics Japan, LLC

Closing Address

- 17:30 – 17:40

Masaru Iwasaki, Program Director

Japan Agency for Medical Research and Development